Angiotensin system inhibitors as adjunctive therapy in esophageal adenocarcinoma: hypothesis-generating insights from incidental use during trimodal treatment
JavaScript is disabled for your browser. Some features of this site may not work without it.
Angiotensin system inhibitors as adjunctive therapy in esophageal adenocarcinoma: hypothesis-generating insights from incidental use during trimodal treatment